From 9f0690f27b83f363c93a5bdad77483e66d91dba2 Mon Sep 17 00:00:00 2001 From: "John J. Dziak" Date: Mon, 1 Mar 2021 20:36:44 -0500 Subject: [PATCH 1/7] Cite a recent JAMA editorial supporting your claim about poverty as driver https://jamanetwork.com/journals/jama/fullarticle/2775687 --- content/40.inequality.md | 3 ++- 1 file changed, 2 insertions(+), 1 deletion(-) diff --git a/content/40.inequality.md b/content/40.inequality.md index 2e4e0080d..ad1e36620 100644 --- a/content/40.inequality.md +++ b/content/40.inequality.md @@ -152,7 +152,8 @@ Similarly, preliminary findings indicate that nutritional status (e.g., vitamin Taken together, the evidence suggests that low-income workers who face greater exposure to SARS-CoV-2 due to their home or work conditions are also more likely to face environmental and social stressors associated with increased inflammation, and therefore with increased risk from COVID-19. In particular, structural racism can play an important role on disease severity after SARS-CoV-2 exposure, due to consequences of racism which include an increased likelihood of poverty and its associated food and housing instability. COVID-19 can thus be considered a "syndemic", or a synergistic interaction between several epidemics [@doi:10.1002/ajhb.23482]. -As a result, it is not surprising that people from minoritized backgrounds and/or with certain pre-existing conditions are more likely to suffer severe effects of COVID-19, but these "risk factors" are likely to be causally linked to poverty. +As a result, it is not surprising that people from minoritized backgrounds and/or with certain pre-existing conditions are more likely to suffer severe effects of COVID-19, but these "risk factors" are likely to be causally linked to poverty +[@doi:10.1001/jama.2020.26443]. #### Access to Treatment From 2527e804c79aa0fad993e432ab99a9f1860caaef Mon Sep 17 00:00:00 2001 From: Ronan Lordan <62627112+RLordan@users.noreply.github.com> Date: Tue, 2 Mar 2021 22:34:10 -0500 Subject: [PATCH 2/7] Small Sputnik V updates Minor updates to the sputnik v section while prepping vaccine distribution info. @rando2 --- content/22.vaccines.md | 13 +++++++++++-- 1 file changed, 11 insertions(+), 2 deletions(-) diff --git a/content/22.vaccines.md b/content/22.vaccines.md index 817fec4a6..7d54fd28b 100644 --- a/content/22.vaccines.md +++ b/content/22.vaccines.md @@ -180,7 +180,7 @@ As of December 11, 2020, the United States FDA approved this vaccine under an em #### Sputnik-V (Gam-COVID-Vac and Gam-COVID-Vac-Lyo) -The vaccine Gam-COVID-Vac, nicknamed Sputnik V in reference to the space race, was developed by the Gamaleya National Center of Epidemiology and Microbiology in Moscow. +The vaccine Gam-COVID-Vac, nicknamed Sputnik V in reference to the space race and "V for vaccine", was developed by the Gamaleya National Center of Epidemiology and Microbiology in Moscow. Gamaleya is an organization with prior experience using the adenovirus platform for the development of vaccines for _Middle East respiratory syndrome-related coronavirus_ and Ebola virus, although neither of the previous vaccines were internationally licensed [@url:https://www.who.int/immunization/sage/meetings/2018/october/2_Ebola_SAGE2018Oct_BgDoc_20180919.pdf]. The development of Sputnik V was financed by the Russian Direct Investment Fund [@doi:10/ft7j; @doi:10/ghs3sn]. Sputnik V is a replication-deficient recombinant adenovirus (rAd) vaccine that combines two adenovirus vectors, rAd26-S and rAd5-S, that express the full-length SARS-CoV-2 spike glycoprotein. @@ -234,8 +234,17 @@ Of the 707 vaccinated healthcare workers, 71.3% of the 96.6% of respondents repo Of these individuals, 68% experienced joint and muscle pain, 54% had injection site pain, 11% reported redness and swelling, 40% had a fever, and 5% reported diarrhea. Only 5% of the vaccinated participants experienced serious adverse events that required medical attention, of which one was monitored as an inpatient. +Additionally, an Independent assessment of Sputnik V in a phase II clinical trial in India found the vaccine to be effective, but the data is not yet publicly available [https://www.reuters.com/article/health-coronavirus-india-vaccine-idUSL4N2JM2XA]. +On December 21st, 2020, Gamaleya, AstraZeneca, R-Pharm, and the Russian Direct Investment Fund agreed to assess the safety and immunogenicity of the combined use of components of the AstraZeneca and University of Oxford AZD1222 (ChAdOx1) vaccine and the rAd26-S component of the Sputnik V vaccine in clinical trials [@url:https://rdif.ru/Eng_fullNews/6220/]. +This agreement hopes to establish scientific and business relations between the entities with an aim to co-developing a vaccine with long-term immunization. +The trial, which will begin enrollment soon, will include 100 participants in a phase II open-label study and is hoped to be complete within 6 months. +Participants will first receive an intramuscular dose of AZD1222 on day 1, followed by a dose of rAd26 on day 29. +Participants will be monitored from day 1 for 180 days in total. +The primary outcomes measured will include incidence of serious adverse events post first dose until the end of the study. +Secondary outcome measures will include incidence of local and systemic adverse events 7 days post each dose, a time course of antibody responses for the Spike protein and the presence of anti-SARS-CoV-2 neutralizing antibodies [@clinicaltrials:NCT04686773]. + Overall, there is hesitancy surrounding the management of the Sputnik V vaccine approval process and concerns over whether the efficacy data may be inflated due to a lack of asymptomatic testing within the trial. -However, further trials are underway, which will likely shed light on the overall efficacy and safety of the Sputnik V vaccine regimen. +However, the results of the phase III study were promising and further trials are underway, which will likely shed light on the overall efficacy and safety of the Sputnik V vaccine regimen. There may be some advantage to the Sputnik V approach including the favorable storage conditions afforded by choice between a frozen and lyophilized vaccine. Furthermore, the producers of Gam-COVID-Vac state that they can produce the vaccine at a cost of less than $10 per dose or less than $20 per patient [@url:https://sputnikvaccine.com]. From 4ec400d16fccef9fb5e70568c00abefaa5f3096d Mon Sep 17 00:00:00 2001 From: Ronan Lordan <62627112+RLordan@users.noreply.github.com> Date: Tue, 2 Mar 2021 22:42:42 -0500 Subject: [PATCH 3/7] Update content/22.vaccines.md --- content/22.vaccines.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/content/22.vaccines.md b/content/22.vaccines.md index 7d54fd28b..9375142cc 100644 --- a/content/22.vaccines.md +++ b/content/22.vaccines.md @@ -244,7 +244,7 @@ The primary outcomes measured will include incidence of serious adverse events p Secondary outcome measures will include incidence of local and systemic adverse events 7 days post each dose, a time course of antibody responses for the Spike protein and the presence of anti-SARS-CoV-2 neutralizing antibodies [@clinicaltrials:NCT04686773]. Overall, there is hesitancy surrounding the management of the Sputnik V vaccine approval process and concerns over whether the efficacy data may be inflated due to a lack of asymptomatic testing within the trial. -However, the results of the phase III study were promising and further trials are underway, which will likely shed light on the overall efficacy and safety of the Sputnik V vaccine regimen. +However, the interim results of the phase III study were promising and further trials are underway, which will likely shed light on the overall efficacy and safety of the Sputnik V vaccine regimen. There may be some advantage to the Sputnik V approach including the favorable storage conditions afforded by choice between a frozen and lyophilized vaccine. Furthermore, the producers of Gam-COVID-Vac state that they can produce the vaccine at a cost of less than $10 per dose or less than $20 per patient [@url:https://sputnikvaccine.com]. From b1aa9820cfd93e483659a22d8b37a6102054ce19 Mon Sep 17 00:00:00 2001 From: HM Rando Date: Wed, 3 Mar 2021 15:28:11 -0500 Subject: [PATCH 4/7] Update content/40.inequality.md --- content/40.inequality.md | 3 +-- 1 file changed, 1 insertion(+), 2 deletions(-) diff --git a/content/40.inequality.md b/content/40.inequality.md index ad1e36620..4edff7963 100644 --- a/content/40.inequality.md +++ b/content/40.inequality.md @@ -152,8 +152,7 @@ Similarly, preliminary findings indicate that nutritional status (e.g., vitamin Taken together, the evidence suggests that low-income workers who face greater exposure to SARS-CoV-2 due to their home or work conditions are also more likely to face environmental and social stressors associated with increased inflammation, and therefore with increased risk from COVID-19. In particular, structural racism can play an important role on disease severity after SARS-CoV-2 exposure, due to consequences of racism which include an increased likelihood of poverty and its associated food and housing instability. COVID-19 can thus be considered a "syndemic", or a synergistic interaction between several epidemics [@doi:10.1002/ajhb.23482]. -As a result, it is not surprising that people from minoritized backgrounds and/or with certain pre-existing conditions are more likely to suffer severe effects of COVID-19, but these "risk factors" are likely to be causally linked to poverty -[@doi:10.1001/jama.2020.26443]. +As a result, it is not surprising that people from minoritized backgrounds and/or with certain pre-existing conditions are more likely to suffer severe effects of COVID-19, but these "risk factors" are likely to be causally linked to poverty [@doi:10.1001/jama.2020.26443]. #### Access to Treatment From 11c1c60c10d301cfa136a8b13b91d7e9267b7380 Mon Sep 17 00:00:00 2001 From: Ronan Lordan <62627112+RLordan@users.noreply.github.com> Date: Wed, 3 Mar 2021 15:54:29 -0500 Subject: [PATCH 5/7] Update content/22.vaccines.md Co-authored-by: HM Rando --- content/22.vaccines.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/content/22.vaccines.md b/content/22.vaccines.md index 9375142cc..d9f70a806 100644 --- a/content/22.vaccines.md +++ b/content/22.vaccines.md @@ -234,7 +234,7 @@ Of the 707 vaccinated healthcare workers, 71.3% of the 96.6% of respondents repo Of these individuals, 68% experienced joint and muscle pain, 54% had injection site pain, 11% reported redness and swelling, 40% had a fever, and 5% reported diarrhea. Only 5% of the vaccinated participants experienced serious adverse events that required medical attention, of which one was monitored as an inpatient. -Additionally, an Independent assessment of Sputnik V in a phase II clinical trial in India found the vaccine to be effective, but the data is not yet publicly available [https://www.reuters.com/article/health-coronavirus-india-vaccine-idUSL4N2JM2XA]. +Additionally, an Independent assessment of Sputnik V in a phase II clinical trial in India found the vaccine to be effective, but the data is not yet publicly available [@url:https://www.reuters.com/article/health-coronavirus-india-vaccine-idUSL4N2JM2XA]. On December 21st, 2020, Gamaleya, AstraZeneca, R-Pharm, and the Russian Direct Investment Fund agreed to assess the safety and immunogenicity of the combined use of components of the AstraZeneca and University of Oxford AZD1222 (ChAdOx1) vaccine and the rAd26-S component of the Sputnik V vaccine in clinical trials [@url:https://rdif.ru/Eng_fullNews/6220/]. This agreement hopes to establish scientific and business relations between the entities with an aim to co-developing a vaccine with long-term immunization. The trial, which will begin enrollment soon, will include 100 participants in a phase II open-label study and is hoped to be complete within 6 months. From d11774b0982e7eb182eb84545fb0391f47801a44 Mon Sep 17 00:00:00 2001 From: Ronan Lordan <62627112+RLordan@users.noreply.github.com> Date: Wed, 3 Mar 2021 15:55:09 -0500 Subject: [PATCH 6/7] Update content/22.vaccines.md Co-authored-by: HM Rando --- content/22.vaccines.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/content/22.vaccines.md b/content/22.vaccines.md index d9f70a806..cde2ccbd3 100644 --- a/content/22.vaccines.md +++ b/content/22.vaccines.md @@ -236,7 +236,7 @@ Only 5% of the vaccinated participants experienced serious adverse events that r Additionally, an Independent assessment of Sputnik V in a phase II clinical trial in India found the vaccine to be effective, but the data is not yet publicly available [@url:https://www.reuters.com/article/health-coronavirus-india-vaccine-idUSL4N2JM2XA]. On December 21st, 2020, Gamaleya, AstraZeneca, R-Pharm, and the Russian Direct Investment Fund agreed to assess the safety and immunogenicity of the combined use of components of the AstraZeneca and University of Oxford AZD1222 (ChAdOx1) vaccine and the rAd26-S component of the Sputnik V vaccine in clinical trials [@url:https://rdif.ru/Eng_fullNews/6220/]. -This agreement hopes to establish scientific and business relations between the entities with an aim to co-developing a vaccine with long-term immunization. +This agreement hopes to establish scientific and business relations between the entities with an aim to co-develop a vaccine providing long-term immunization. The trial, which will begin enrollment soon, will include 100 participants in a phase II open-label study and is hoped to be complete within 6 months. Participants will first receive an intramuscular dose of AZD1222 on day 1, followed by a dose of rAd26 on day 29. Participants will be monitored from day 1 for 180 days in total. From 0207a5ee13b55f4139bb02c878ba5d8aded41451 Mon Sep 17 00:00:00 2001 From: HM Rando Date: Wed, 3 Mar 2021 16:05:50 -0500 Subject: [PATCH 7/7] Add Pharm to dictionary --- build/assets/custom-dictionary.txt | 1 + 1 file changed, 1 insertion(+) diff --git a/build/assets/custom-dictionary.txt b/build/assets/custom-dictionary.txt index 6547f499a..e49f0926b 100644 --- a/build/assets/custom-dictionary.txt +++ b/build/assets/custom-dictionary.txt @@ -493,6 +493,7 @@ Paulo PepSite Perrin Pfaender +Pharm Phosphoinositol Picornaviridae Plitt